Tofacitinib is associated with attainment of the minimally important reduction in axial magnetic resonance imaging inflammation in ankylosing spondylitis patients.

In general, numerically more patients in the pooled 5 and 10 mg BID group who achieved MIC in SI joint or spine also achieved clinical responses; however, these differences did not reach statistical significance for any clinical outcome.

also in 111,027 other papers